Recursion Pharmaceuticals enters amendment to master agreement with Tempus

Recursion Pharmaceuticals said it entered into an amendment to its master agreement with Tempus, extending the agreement term from five to six years and eliminating the company's right to terminate the agreement for convenience. The amendment was dated Sept. 15, 2026.